Medzome Life Sciencez Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 08-12-2024
- Paid Up Capital ₹ 3.50 M
as on 08-12-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 37.75%
(FY 2021)
- Profit 29.91%
(FY 2021)
- Ebitda -1338.92%
(FY 2021)
- Net Worth -86.15%
(FY 2021)
- Total Assets 15.42%
(FY 2021)
About Medzome Life Sciencez
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.50 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Dudeja, Rakesh Bijarnia, and Arsh Suri serve as directors at the Company.
- CIN/LLPIN
U33110DL2019PTC351437
- Company No.
351437
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Medzome Life Sciencez Private Limited offer?
Medzome Life Sciencez Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Rapid Test Kit, Corona Test Kit.
Who are the key members and board of directors at Medzome Life Sciencez?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Dudeja  | Director | 17-Jun-2019 | Current |
| Arsh Suri | Director | 17-Jun-2019 | Current |
| Rakesh Bijarnia | Director | 17-Jun-2019 | Current |
Financial Performance and Corporate Structure Insights of Medzome Life Sciencez.
Medzome Life Sciencez Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 37.75% increase. The company also saw a substantial improvement in profitability, with a 29.91% increase in profit. The company's net worth observed a substantial decline by a decrease of 86.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medzome Life Sciencez?
In 2021, Medzome Life Sciencez had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Jd Homes And Hospitalities Private LimitedActive 16 years 7 months
Santosh Dudeja is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medzome Life Sciencez?
Unlock and access historical data on people associated with Medzome Life Sciencez, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medzome Life Sciencez, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medzome Life Sciencez's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
